Coare Biotechnology

Pre-clinical

San Diego, United StatesFounded 2018coareholdings.com

Coare Biotechnology is a private, pre-clinical stage company dedicated to designing and developing first-in-class anti-cancer therapeutics that target cancer stem cells responsible for metastasis, therapy resistance, and relapse. Its core technology platform is built around targeting the DCLK1 protein, which marks and drives tumorigenesis in multiple solid tumors. The company's scientific foundation originated at the University of Oklahoma Health Sciences Center and has been licensed to Coare, with development supported by non-dilutive NIH funding and collaborations with academic institutions.

Founded

2018

Focus

AntibodiesBiologicsSmall Molecules

AI Company Overview

Technology Platform

Platform targeting the DCLK1 protein, a master regulator that marks cancer stem cells in solid tumors, using immunotherapy and nanomedicine approaches to disrupt tumorigenesis and metastasis.

Opportunities

The company has the opportunity to establish a first-in-class franchise targeting DCLK1 in multiple high-mortality solid tumors, addressing the root cause of metastasis.

Success could lead to partnerships with large pharma seeking novel oncology mechanisms or an attractive acquisition.

Risk Factors

Key risks include the pre-clinical nature of its platform, reliance on grant funding which may be insufficient for clinical trials, and the high failure rate inherent in novel oncology drug development.

Competition in the broader cancer stem cell field is also a factor.

Competitive Landscape

Direct competition targeting DCLK1 is limited, providing a potential first-mover advantage. Broader competition comes from large pharma immunotherapies and other companies targeting cancer stem cell pathways (e.g., Wnt, Notch). Coare's differentiation is its specific focus on DCLK1 and its multi-modal therapeutic approach.